DOCSLIB.ORG

Immunophenotyping Mouse Cell Surface Antigens

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Mouse Cell Surface Antigens: Nomenclature and Immunophenotyping1 Lily Lai,* Noosheen Alaverdi,* Lois Maltais,† and Herbert C. Morse III2‡ This paper reviews cell surface Ags expressed on mouse hemopoietic and nonhemopoietic cells. The review will cover molecules included in the cluster of differentiation (CD) from CD1 to CD166 and lymphocyte Ag (Ly) series from Ly-1 to Ly-81 as well as some new Ags without current CD or Ly assignments. In addition to an update on mouse nomenclature, there will be a discussion of some known functions of the molecules and brief comments on the use of particular Ags for immunophenotyping of cell subsets. Several novel markers mentioned may prove useful in mouse immunology research. The Journal of Immunology, 1998, 160: 3861–3868. olecules on the surface of hemopoietic cells play im- ceptor, and blind (multilineage panels). More information can be portant roles in the development and function of these obtained from the HLDA website (http://mol.genes.nig.ac.jp/hlda) M cells and have permitted us to understand the immune or Protein Reviews on the worldwide web (http://www.ncbi.nlm. system in increasingly great depth. In recent years, it has become nih.gov/prow). clear that there is a considerable amount of cross-talk between Over the years, the Committee on Standardized Genetic Nomen- cells of the hemopoietic system and nonhemopoietic cells, with clature for Mice has continued to assign new Ly and CD names to much of this interplay mediated by cell surface molecules. This novel genes and Ags. Since the last update (2), many new Ly review includes a discussion of cell surface Ags expressed on both designations have been assigned; for example, the F4/80 Ag, hemopoietic and nonhemopoietic cells. In addition to an update on whose gene has recently been cloned, was given the designation nomenclature, there will be a discussion of functions of the mol- Ly-71. (See Table I for an update of the Ly nomenclature.) The ecules, when known, and brief comments on the use of particular human homologues of a number of mouse Ags or genes, including Ags for immunophenotyping cell subsets. The review will cover members of the Ly-6 and Ly-49 families, have not yet been de- molecules included in the cluster of differentiation (CD)3 and lym- finitively identified. When a mouse Ly Ag is identified as a human phocyte Ag (Ly) series as well as some new Ags without current CD homologue, the Ly number for the molecule is withdrawn and CD or Ly assignments. reassigned the appropriate CD number. If the mouse molecule was As discussed in previous reviews (1, 2), there is a need for encoded by a gene that is assigned a Ly number, that gene name is unifying mouse and human nomenclature to facilitate communi- withdrawn and reassigned a Cd number, unless another gene name cation between researchers studying these species. For mice, the was agreed on by the human and mouse nomenclature groups. As Ly nomenclature was originally devised to classify genes identified one example, the Ly-5 molecule of the mouse, encoded by Ly5, through serologic studies of inbred strains; for humans, the CD was assigned CD45 in the human nomenclature for Ags and the nomenclature originates from mAb reactivity to human Ags. Hu- gene name CD45. The mouse designations were changed to CD45 man leukocyte differentiation Ag (HLDA) workshops assign each for the Ag and, initially, Cd45 for the gene. More recently, the CD based on the same reactivity to one human Ag by at least two human and mouse nomenclature committees adopted the gene Pt- mAbs; provisional CDw are sometimes given to clusters not well prc for the genes encoding CD45 in both species. characterized or represented by only one mAb (3). The Sixth Multiple studies, including biochemical analysis, cloning, func- HLDA Workshop, which took place in 1996, resulted in the as- tional, and immunologic assays, are necessary to confirm homo- signment of novel CDs with new designations spanning CD131 to logues between species. In addition to differences in DNA se- CD166. mAb submitted to the workshop are tested by laboratories quence, evolutionary divergence between mice and humans may participating in the following sections: T cell, B cell, NK cell, also be manifested in Ag distribution. Notable examples include adhesion, endothelial, myeloid, nonlineage, platelet, cytokine re- CD2, CD90 (Thy-1), and perhaps CD34. Table II reflects several novel mouse CD homologues that have been identified via cloning, Abs, or protein probes, such as the use of ligand-Ig fusion proteins. † *PharMingen, San Diego, CA 92121; Nomenclature Coordinator/Mouse Genome, Some molecules are particularly useful as phenotyping markers The Jackson Laboratory, Bar Harbor, ME 04609; and ‡Laboratory of Immunopathol- ogy, National Institute of Allergy and Infectious Diseases, National Institutes of for different cell subpopulations. The large number of well-char- Health, Bethesda, MD 20892 acterized mAbs has facilitated identifying cell types based on their Received for publication September 26, 1997. Accepted for publication December surface phenotypes. For additional reference, a review of mAbs to 24, 1997. human and murine CD Ags has been made available (4). It should The costs of publication of this article were defrayed in part by the payment of page be noted that only a few Ags have restricted lineage distributions; charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. most cell surface molecules exhibit a broader distribution than ini- 1 The Mouse Genome Database Project is supported by National Institutes of Health tially reported. Multiparameter immunoanalysis, therefore, is re- Grant HG00330. quired to isolate different cell types. Below is a summary of rele- 2 Address correspondence and reprint requests to Dr. Dr. Herbert C. Morse III, Lab- vant Ags associated with cell lineages. oratory of Immunopathology, National Institute of Allergy and Infectious Diseases, Building 7, Room 304, National Institutes of Health, Bethesda, MD 20892–0760. B cells 3 Abbreviations used in this paper: CD, cluster of differentiation; Ly, lymphocyte antigen; HLDA, human leukocyte differentiation antigen; KIR, killing inhibitory re- In the mouse, one of the most commonly used pan-B cell markers ceptor; DC, dendritic cell. is identified by the mAb RA3-6B2 (CD45R/B220); however, this Copyright © 1998 by The American Association of Immunologists 0022-1767/98/$02.00 3862 MOUSE CELL SURFACE Ags Table I. Mouse Ly molecules a Ly Status Current CD Previous Designation Gene Symbol Chromosome Ly-1 Withdrawn CD5 Ly-35 Cd5 19 Ly-2 Withdrawn Cd8a Cd8a 6 Ly-3 Withdrawn CD8b CD8b 6 Ly-4 Withdrawn CD4 CD4 6 Ly-5 Withdrawn CD45 Ptprc 1 Ly-6A TAP, Sca-1, Ly-6D Ly6a 15 Ly-6B Ly6b 15 Ly-6C Ly6c 15 Ly-6D ThB, Ly-61 Ly6d 15 Ly-6E TSA-1, Sca-2, Ly-67 Ly6e 15 Ly-6F Ly6f 15 Ly-6G Ly6g 15 Ly-7 Ly7 16 Ly-8 Ly8 Unknown Ly-9 Ly9 1 Ly-10 Withdrawn CD98 CD98 19 Ly-11 Ly11 2 Ly-12 Withdrawn CD5 Allele of Ly-1 Cd5 19 Ly-13 Ly13 Unknown Ly-14 Ly14 7 Ly-15 Withdrawn CD11a LFA-1 Itgal 7 Ly-16 Ly-18 Ly16 12 Ly-17 Withdrawn CD16/32 Fcgr2b 1 Ly-18 Ly-m18 Ly18 12 Ly-19 Withdrawn CD72 Ly-m19, Lyb-2 Cd72 4 Ly-20 Ly-22a Ly20 4 Ly-21 Withdrawn CD11a Allele of Ly-15, LFA-1 Itgal 7 Ly-22 Withdrawn CD62L L-selectin, MEL-14 Sell 1 Ly-23 Ly23 2 Ly-24 Withdrawn CD44 Pgp-1 CD44 2 Ly-25 Ly25 2 Ly-26 Ly26 Unknown Ly-27 Withdrawn Ly-6 Ly6 15 Ly-28 Ly28 13 Ly-29 Ly29 4 Ly-30 Ly30 Unknown Ly-31 Ly31 4 Ly-32 Withdrawn CD72 Lyb-2 Cd72 4 Ly-33 Ly33 1 Ly-34 Ly34 13 Ly-35 Withdrawn CD8a Allele of Ly-2 Cd8a 6 Ly-36 Ly36 6 Ly-37 Withdrawn CD2 Cd2 3 Ly-38 Withdrawn CD1d Cd1d 3 Ly-39 Ly39 17 Ly-40 Withdrawn CD11b Mac-1 Itgam Unknown Ly-41 Npps 10 Ly-42 Withdrawn CD23 FceRIIa Fcer2a 8 Ly-43 Withdrawn CD25 IL-2Ra IL2ra 2 Ly-44 Withdrawn CD20 Cd20 19 Ly-45 Ly45 Unknown Ly-46 Ly46 Unknown Ly-47 Withdrawn CD54 ICAM-1 Icam1 9 Ly-48 Withdrawn CD43 leukosialin Spn 7 Ly-49A Withdrawn A1 Klra1 6 Ly-49B Withdrawn Klra2 6 Ly-49C Withdrawn 5E 6 Klra3 6 Ly-49D Withdrawn Klra4 6 Ly-49E Withdrawn Klra5 6 Ly-49F Withdrawn Klra6 6 Ly-49G Withdrawn LGL-1 Klra7 6 Ly-49H Withdrawn Klra8 6 Ly-49I Withdrawn Klra9 6 Ly-50 FceRI, high affinity Fcer1g 1 Ly-51 6C3/BP-1 Enpep 3 Ly-52 Withdrawn CD24a HSA Cd24a 10 Ly-53 Withdrawn CD80 B7-1 Cd80 16 Ly-54 Withdrawn CD79a mb-1, lga Cd79a 7 Ly-55 Withdrawn CD161 NKR-P1A Klrb1 6 Ly-56 Withdrawn CD152 CTLA-4 Cd152 1 Ly-57 Lyw-57 Ly57 19 Ly-58 Withdrawn CD86 B7-2 CD86 16 Ly-59 Withdrawn NK1.1, NKR-P1C Klrb3 6 Ly-60 Withdrawn CD102 ICAM-2 Icam2 11 Continued The Journal of Immunology 3863 Table I. continued Ly Status Current CD Previous Designation Gene Symbol Chromosome Ly-61 Withdrawn ThB Ly6d 15 Ly-62 Withdrawn CD154 gp39 Cd401 X Ly-63 Withdrawn CD136 4-1BB Cd136 4 Ly-63L 4-1BB ligand Ly631 17 Ly-64 14/A10 Ly64 13 Ly-65 Withdrawn CD157 BP-3 Bp3 5 Ly-66 LAG3 Lag3 6 Ly-67 Withdrawn TSA-1, Sca-2 Ly6e 15 Ly-68 AA4.1 Ly68 Unknown Ly-69 Ly-69 Itgb7 15 Ly-70 Withdrawn CD134 OX-40 Txgp1 4 Ly-70L OX-40L Txgp1l 1 Ly-71 F4/80 Emr1 17 Ly-72 Withdrawn CD135 Flk-2/Flt3 Flt3 5 Ly-72L Flt3 L Flt3l 7 Ly-73 Flk-1 Flk1 5 Ly-74 Ep-CAM Ly74 Unknown Ly-75 DEC-205 Ly75 Unknown Ly-76 TER-119 Ly76 Unknown Ly-77 GL7 Ly77 Unknown Ly-78 RP-105 Ly78 Unknown Ly-79 33D1 Ly79 Unknown Ly-80 Mir Unknown Ly-81 Trail Unknown Lyb-2 Withdrawn CD72 Ly32 CD72 4 Lyb-3 Lyb3 Unknown Lyb-4 Lyb4 4 Lyb-5 Lyb5 Unknown Lyb-6 Lyb6 4 Lyb-7 Lyb7 12 Lyb-8 Withdrawn CD22 Cd22 7 a References for all Ly molecules have been entered into the Mouse Genome Database (http://www.informatics.jax.org).
Recommended publications
  • ENSG Gene Encodes Effector TCR Pathway Costimulation Inhibitory/Exhaustion Synapse/Adhesion Chemokines/Receptors

    ENSG Gene Encodes Effector TCR Pathway Costimulation Inhibitory/Exhaustion Synapse/Adhesion Chemokines/Receptors

    ENSG Gene Encodes Effector TCR pathway Costimulation Inhibitory/exhaustion Synapse/adhesion Chemokines/receptors ENSG00000111537 IFNG IFNg x ENSG00000109471 IL2 IL-2 x ENSG00000232810 TNF TNFa x ENSG00000271503 CCL5 CCL5 x x ENSG00000139187 KLRG1 Klrg1 x ENSG00000117560 FASLG Fas ligand x ENSG00000121858 TNFSF10 TRAIL x ENSG00000134545 KLRC1 Klrc1 / NKG2A x ENSG00000213809 KLRK1 Klrk1 / NKG2D x ENSG00000188389 PDCD1 PD-1 x x ENSG00000117281 CD160 CD160 x x ENSG00000134460 IL2RA IL-2 receptor x subunit alpha ENSG00000110324 IL10RA IL-10 receptor x subunit alpha ENSG00000115604 IL18R1 IL-18 receptor 1 x ENSG00000115607 IL18RAP IL-18 receptor x accessory protein ENSG00000081985 IL12RB2 IL-12 receptor x beta 2 ENSG00000186810 CXCR3 CXCR3 x x ENSG00000005844 ITGAL CD11a x ENSG00000160255 ITGB2 CD18; Integrin x x beta-2 ENSG00000156886 ITGAD CD11d x ENSG00000140678 ITGAX; CD11c x x Integrin alpha-X ENSG00000115232 ITGA4 CD49d; Integrin x x alpha-4 ENSG00000169896 ITGAM CD11b; Integrin x x alpha-M ENSG00000138378 STAT4 Stat4 x ENSG00000115415 STAT1 Stat1 x ENSG00000170581 STAT2 Stat2 x ENSG00000126561 STAT5a Stat5a x ENSG00000162434 JAK1 Jak1 x ENSG00000100453 GZMB Granzyme B x ENSG00000145649 GZMA Granzyme A x ENSG00000180644 PRF1 Perforin 1 x ENSG00000115523 GNLY Granulysin x ENSG00000100450 GZMH Granzyme H x ENSG00000113088 GZMK Granzyme K x ENSG00000057657 PRDM1 Blimp-1 x ENSG00000073861 TBX21 T-bet x ENSG00000115738 ID2 ID2 x ENSG00000176083 ZNF683 Hobit x ENSG00000137265 IRF4 Interferon x regulatory factor 4 ENSG00000140968 IRF8 Interferon
  • Screening and Identification of Key Biomarkers in Clear Cell Renal Cell Carcinoma Based on Bioinformatics Analysis

    Screening and Identification of Key Biomarkers in Clear Cell Renal Cell Carcinoma Based on Bioinformatics Analysis

    bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423889; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Screening and identification of key biomarkers in clear cell renal cell carcinoma based on bioinformatics analysis Basavaraj Vastrad1, Chanabasayya Vastrad*2 , Iranna Kotturshetti 1. Department of Biochemistry, Basaveshwar College of Pharmacy, Gadag, Karnataka 582103, India. 2. Biostatistics and Bioinformatics, Chanabasava Nilaya, Bharthinagar, Dharwad 580001, Karanataka, India. 3. Department of Ayurveda, Rajiv Gandhi Education Society`s Ayurvedic Medical College, Ron, Karnataka 562209, India. * Chanabasayya Vastrad [email protected] Ph: +919480073398 Chanabasava Nilaya, Bharthinagar, Dharwad 580001 , Karanataka, India bioRxiv preprint doi: https://doi.org/10.1101/2020.12.21.423889; this version posted December 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Clear cell renal cell carcinoma (ccRCC) is one of the most common types of malignancy of the urinary system. The pathogenesis and effective diagnosis of ccRCC have become popular topics for research in the previous decade. In the current study, an integrated bioinformatics analysis was performed to identify core genes associated in ccRCC. An expression dataset (GSE105261) was downloaded from the Gene Expression Omnibus database, and included 26 ccRCC and 9 normal kideny samples. Assessment of the microarray dataset led to the recognition of differentially expressed genes (DEGs), which was subsequently used for pathway and gene ontology (GO) enrichment analysis.
  • (CD147) Is Induced by C/Ebpβ and Is Differentially Expressed in ALK+

    (CD147) Is Induced by C/Ebpβ and Is Differentially Expressed in ALK+

    Laboratory Investigation (2017) 97, 1095–1102 © 2017 USCAP, Inc All rights reserved 0023-6837/17 EMMPRIN (CD147) is induced by C/EBPβ and is differentially expressed in ALK+ and ALK − anaplastic large-cell lymphoma Janine Schmidt1, Irina Bonzheim1, Julia Steinhilber1, Ivonne A Montes-Mojarro1, Carlos Ortiz-Hidalgo2, Wolfram Klapper3, Falko Fend1 and Leticia Quintanilla-Martínez1 Anaplastic lymphoma kinase-positive (ALK+) anaplastic large-cell lymphoma (ALCL) is characterized by expression of oncogenic ALK fusion proteins due to the translocation t(2;5)(p23;q35) or variants. Although genotypically a T-cell lymphoma, ALK+ ALCL cells frequently show loss of T-cell-specific surface antigens and expression of monocytic markers. C/EBPβ, a transcription factor constitutively overexpressed in ALK+ ALCL cells, has been shown to play an important role in the activation and differentiation of macrophages and is furthermore capable of transdifferentiating B-cell and T-cell progenitors to macrophages in vitro. To analyze the role of C/EBPβ for the unusual phenotype of ALK+ ALCL cells, C/EBPβ was knocked down by RNA interference in two ALK+ ALCL cell lines, and surface antigen expression profiles of these cell lines were generated using a Human Cell Surface Marker Screening Panel (BD Biosciences). Interesting candidate antigens were further analyzed by immunohistochemistry in primary ALCL ALK+ and ALK − cases. Antigen expression profiling revealed marked changes in the expression of the activation markers CD25, CD30, CD98, CD147, and CD227 after C/EBPβ knockdown. Immunohistochemical analysis confirmed a strong, membranous CD147 (EMMPRIN) expression in ALK+ ALCL cases. In contrast, ALK − ALCL cases showed a weaker CD147 expression.
  • Expression of the Hematopoietic Stem Cell Antigen CD34 on Blood and Bone Marrow Monoclonal Plasma Cells from Patients with Multiple Myeloma

    Expression of the Hematopoietic Stem Cell Antigen CD34 on Blood and Bone Marrow Monoclonal Plasma Cells from Patients with Multiple Myeloma

    Bone Marrow Transplantation, (1997) 19, 553–556 1997 Stockton Press All rights reserved 0268–3369/97 $12.00 Expression of the hematopoietic stem cell antigen CD34 on blood and bone marrow monoclonal plasma cells from patients with multiple myeloma T Kimlinger1 and TE Witzig2 1Department of Laboratory Medicine and 2Division of Internal Medicine and Hematology, Mayo Clinic and Mayo Foundation, Rochester, MN, USA Summary: led to strategies to deplete the tumor cells from the harvest product prior to reinfusion of the stem cells. Monoclonal plasma cells (CD38+CD45−/dim) are typi- One of the current attempts at purifying the harvest pro- cally present in the blood of patients with active mye- duct uses antibody to the CD34 antigen to positively select loma and can contaminate stem cell harvests. This has and enrich hematopoietic stem cells and in the process led to strategies that select CD34+ cells for use in auto- purge the stem cell product of tumor cells and T cells.11–13 logous stem cell transplantation with the goal of The CD34 antigen identifies a lymphohematopoietic stem decreasing tumor cell contamination. The aim of this cell, is present on 1–5% of adult bone marrow cells, and study was to learn if the CD34 antigen is expressed on is expressed on early B cells. The characteristics of this monoclonal plasma cells in the blood or marrow of important antigen and its clinical relevance have recently patients with multiple myeloma. We used three-color been reviewed.14 CD34+ hematopoietic cells from blood or flow cytometry (surface CD38;CD45 and cytoplasmic marrow can reconstitute hematopoiesis after high-dose kappa or lambda) to identify monoclonal plasma cells therapy programs.15 The number of CD34+ cells reinfused in the blood (n = 24) and marrow (n = 37) from patients predicts the time to engraftment.16,17 with plasma cell proliferative disorders.
  • IL-7 Receptor Blockade Blunts Antigen-Specific Memory T Cell

    IL-7 Receptor Blockade Blunts Antigen-Specific Memory T Cell

    ARTICLE DOI: 10.1038/s41467-018-06804-y OPEN IL-7 receptor blockade blunts antigen-specific memory T cell responses and chronic inflammation in primates Lyssia Belarif1,2, Caroline Mary1,2, Lola Jacquemont1, Hoa Le Mai1, Richard Danger1, Jeremy Hervouet1, David Minault1, Virginie Thepenier1,2, Veronique Nerrière-Daguin1, Elisabeth Nguyen1, Sabrina Pengam1,2, Eric Largy3,4, Arnaud Delobel3, Bernard Martinet1, Stéphanie Le Bas-Bernardet1,5, Sophie Brouard1,5, Jean-Paul Soulillou1, Nicolas Degauque 1,5, Gilles Blancho1,5, Bernard Vanhove1,2 & Nicolas Poirier1,2 1234567890():,; Targeting the expansion of pathogenic memory immune cells is a promising therapeutic strategy to prevent chronic autoimmune attacks. Here we investigate the therapeutic efficacy and mechanism of new anti-human IL-7Rα monoclonal antibodies (mAb) in non-human primates and show that, depending on the target epitope, a single injection of antagonistic anti-IL-7Rα mAbs induces a long-term control of skin inflammation despite repeated antigen challenges in presensitized monkeys. No modification in T cell numbers, phenotype, function or metabolism is observed in the peripheral blood or in response to polyclonal stimulation ex vivo. However, long-term in vivo hyporesponsiveness is associated with a significant decrease in the frequency of antigen-specific T cells producing IFN-γ upon antigen resti- mulation ex vivo. These findings indicate that chronic antigen-specific memory T cell responses can be controlled by anti-IL-7Rα mAbs, promoting and maintaining remission in T- cell mediated chronic inflammatory diseases. 1 Centre de Recherche en Transplantation et Immunologie (CRTI) UMR1064, INSERM, Université de Nantes, Nantes 44093, France. 2 OSE Immunotherapeutics, Nantes 44200, France.
  • MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells

    MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells

    Published OnlineFirst July 18, 2013; DOI: 10.1158/0008-5472.CAN-13-0677 Cancer Tumor and Stem Cell Biology Research MUC1 Is a Potential Target for the Treatment of Acute Myeloid Leukemia Stem Cells Dina Stroopinsky1, Jacalyn Rosenblatt1, Keisuke Ito1, Heidi Mills1, Li Yin2, Hasan Rajabi2, Baldev Vasir2, Turner Kufe1, Katarina Luptakova1, Jon Arnason1, Caterina Nardella1, James D. Levine1, Robin M. Joyce1, Ilene Galinsky2, Yoram Reiter3, Richard M. Stone2, Pier Paolo Pandolfi1, Donald Kufe2, and David Avigan1 Abstract Acute myeloid leukemia (AML) is a malignancy of stem cells with an unlimited capacity for self-renewal. MUC1 is a secreted, oncogenic mucin that is expressed aberrantly in AML blasts, but its potential uses to target AML þ À stem cells have not been explored. Here, we report that MUC1 is highly expressed on AML CD34 /lineage / À CD38 cells as compared with their normal stem cell counterparts. MUC1 expression was not restricted to AML þ À CD34 populations as similar results were obtained with leukemic cells from patients with CD34 disease. Engraftment of AML stem cell populations that highly express MUC1 (MUC1high) led to development of leukemia in NOD-SCID IL2Rgammanull (NSG) immunodeficient mice. In contrast, MUC1low cell populations established normal hematopoiesis in the NSG model. Functional blockade of the oncogenic MUC1-C subunit with the peptide inhibitor GO-203 depleted established AML in vivo, but did not affect engraftment of normal hematopoietic cells. Our results establish that MUC1 is highly expressed in AML stem cells and they define the MUC1-C subunit as a valid target for their therapeutic eradication.
  • PAX5 Expression in Acute Leukemias: Higher B-Lineage Specificity Than Cd79a and Selective Association with T(8;21)-Acute Myelogenous Leukemia

    PAX5 Expression in Acute Leukemias: Higher B-Lineage Specificity Than Cd79a and Selective Association with T(8;21)-Acute Myelogenous Leukemia

    [CANCER RESEARCH 64, 7399–7404, October 15, 2004] PAX5 Expression in Acute Leukemias: Higher B-Lineage Specificity Than CD79a and Selective Association with t(8;21)-Acute Myelogenous Leukemia Enrico Tiacci,1 Stefano Pileri,2 Annette Orleth,1 Roberta Pacini,1 Alessia Tabarrini,1 Federica Frenguelli,1 Arcangelo Liso,3 Daniela Diverio,4 Francesco Lo-Coco,5 and Brunangelo Falini1 1Institutes of Hematology and Internal Medicine, University of Perugia, Perugia, Italy; 2Unit of Hematopathology, University of Bologne, Bologne, Italy; 3Section of Hematology, University of Foggia, Foggia, Italy; 4Department of Cellular Biotechnologies and Hematology, University La Sapienza of Rome, Rome, Italy; and 5Department of Biopathology, University Tor Vergata of Rome, Rome, Italy ABSTRACT (13, 16). PAX5 expression also occurs in the adult testis and in the mesencephalon and spinal cord during embryogenesis (17), suggesting an The transcription factor PAX5 plays a key role in the commitment of important role in the development of these tissues. hematopoietic precursors to the B-cell lineage, but its expression in acute Rearrangement of the PAX5 gene through reciprocal chromosomal leukemias has not been thoroughly investigated. Hereby, we analyzed routine biopsies from 360 acute leukemias of lymphoid (ALLs) and mye- translocations has been described in different types of B-cell malig- loid (AMLs) origin with a specific anti-PAX5 monoclonal antibody. Blasts nancies (18–23), and, more recently, PAX5 has also been shown to be from 150 B-cell ALLs showed strong PAX5 nuclear expression, paralleling targeted by aberrant hypermutation in Ͼ50% of diffuse large B-cell that of CD79a in the cytoplasm. Conversely, PAX5 was not detected in 50 lymphomas (24).
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse

    Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse

    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
  • A CD22-Shp1 Phosphatase Axis Controls Integrin Β7 Display and B Cell Function in Mucosal Immunity

    A CD22-Shp1 Phosphatase Axis Controls Integrin Β7 Display and B Cell Function in Mucosal Immunity

    UCSF UC San Francisco Previously Published Works Title A CD22-Shp1 phosphatase axis controls integrin β7 display and B cell function in mucosal immunity. Permalink https://escholarship.org/uc/item/27j4g9rr Journal Nature immunology, 22(3) ISSN 1529-2908 Authors Ballet, Romain Brennan, Martin Brandl, Carolin et al. Publication Date 2021-03-01 DOI 10.1038/s41590-021-00862-z Peer reviewed eScholarship.org Powered by the California Digital Library University of California Europe PMC Funders Group Author Manuscript Nat Immunol. Author manuscript; available in PMC 2021 August 15. Published in final edited form as: Nat Immunol. 2021 March 01; 22(3): 381–390. doi:10.1038/s41590-021-00862-z. Europe PMC Funders Author Manuscripts A CD22-Shp1 phosphatase axis controls integrin β7 display and B cell function in mucosal immunity Romain Ballet1,2,#, Martin Brennan1,2,10, Carolin Brandl3,10, Ningguo Feng1,4, Jeremy Berri1,2, Julian Cheng1,2, Borja Ocón1,2, Amin Alborzian Deh Sheikh5, Alex Marki6, Yuhan Bi1,2, Clare L. Abram7, Clifford A. Lowell7, Takeshi Tsubata5, Harry B. Greenberg1,4, Matthew S. Macauley8,9, Klaus Ley6, Lars Nitschke3, Eugene C. Butcher1,2,# 1The Center for Molecular Biology and Medicine, Veterans Affairs Palo Alto Health Care System and The Palo Alto Veterans Institute for Research, Palo Alto, CA, United States 2Laboratory of Immunology and Vascular Biology, Department of Pathology, School of Medicine, Stanford University, Stanford, CA, United States 3Division of Genetics, Department of Biology, University of Erlangen-Nürnberg, Erlangen,
  • CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy

    CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy

    Published OnlineFirst September 17, 2012; DOI: 10.1158/0008-5472.CAN-12-0173 Cancer Therapeutics, Targets, and Chemical Biology Research CD22 Antigen Is Broadly Expressed on Lung Cancer Cells and Is a Target for Antibody-Based Therapy Joseph M. Tuscano1,2, Jason Kato1, David Pearson3, Chengyi Xiong1, Laura Newell4, Yunpeng Ma1, David R. Gandara1, and Robert T. O'Donnell1,2 Abstract Most patients with lung cancer still die from their disease, necessitating additional options to improve treatment. Here, we provide evidence for targeting CD22, a cell adhesion protein known to influence B-cell survival that we found is also widely expressed in lung cancer cells. In characterizing the antitumor activity of an established anti-CD22 monoclonal antibody (mAb), HB22.7, we showed CD22 expression by multiple approaches in various lung cancer subtypes, including 7 of 8 cell lines and a panel of primary patient specimens. HB22.7 displayed in vitro and in vivo cytotoxicity against CD22-positive human lung cancer cells and tumor xenografts. In a model of metastatic lung cancer, HB22.7 inhibited the development of pulmonary metastasisandextendedoverallsurvival.Thefinding that CD22 is expressed on lung cancer cells is significant in revealing a heretofore unknown mechanism of tumorigenesis and metastasis. Our work suggests that anti- CD22 mAbs may be useful for targeted therapy of lung cancer, a malignancy that has few tumor-specific targets. Cancer Res; 72(21); 5556–65. Ó2012 AACR. Introduction lymphoma (NHL), HB22.7, effectively binds lung cancer cells fi in vitro in vivo In the United States, lung cancer is the most common and mediates speci c and killing.
  • Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model

    Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model

    Downloaded from http://www.jimmunol.org/ by guest on September 25, 2021 T + is online at: average * The Journal of Immunology , 34 of which you can access for free at: 2016; 197:1477-1488; Prepublished online 1 July from submission to initial decision 4 weeks from acceptance to publication 2016; doi: 10.4049/jimmunol.1600589 http://www.jimmunol.org/content/197/4/1477 Molecular Profile of Tumor-Specific CD8 Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A. Waugh, Sonia M. Leach, Brandon L. Moore, Tullia C. Bruno, Jonathan D. Buhrman and Jill E. Slansky J Immunol cites 95 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html http://www.jimmunol.org/content/suppl/2016/07/01/jimmunol.160058 9.DCSupplemental This article http://www.jimmunol.org/content/197/4/1477.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2016 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 25, 2021. The Journal of Immunology Molecular Profile of Tumor-Specific CD8+ T Cell Hypofunction in a Transplantable Murine Cancer Model Katherine A.
  • NKG2D Promotes B1a Cell Development and Protection

    NKG2D Promotes B1a Cell Development and Protection

    NKG2D Promotes B1a Cell Development and Protection against Bacterial Infection Maja Lenartic, Vedrana Jelencic, Biljana Zafirova, Mateja Ozanic, Valentina Marecic, Slaven Jurkovic, Veronika Sexl, This information is current as Marina Santic, Felix M. Wensveen and Bojan Polic of September 25, 2021. J Immunol 2017; 198:1531-1542; Prepublished online 13 January 2017; doi: 10.4049/jimmunol.1600461 http://www.jimmunol.org/content/198/4/1531 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2017/01/12/jimmunol.160046 Material 1.DCSupplemental http://www.jimmunol.org/ References This article cites 45 articles, 18 of which you can access for free at: http://www.jimmunol.org/content/198/4/1531.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 25, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology NKG2D Promotes B1a Cell Development and Protection against Bacterial Infection Maja Lenartic´,* Vedrana Jelencic´,* Biljana Zafirova,*,† Mateja Ozanic,‡ Valentina Marecic´,‡ Slaven Jurkovic´,x Veronika Sexl,{ Marina Santic ´,‡ Felix M.